Lumigan

What is Lumigan?[edit | edit source]

Lumigan (bimatoprost) is a prostaglandin analog used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Bimatoprost

Lumigan 0.01% and 0.03% (bimatoprost ophthalmic solution) is used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity.
It selectively mimics the effects of naturally occurring substances, prostamides.
Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.

No formal drug interaction studies have been conducted with Lumigan.
LUMIGAN® may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Recommended dosage:

One drop in the affected eye(s) once daily in the evening.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.

This medicine is available in fallowing doasage form:

As Solution containing 0.1 mg/mL bimatoprost (LUMIGAN® 0.01%) or containing 0.3 mg/mL bimatoprost (LUMIGAN® 0.03%).

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent.
LUMIGAN 0.01% and 0.03% may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.
LUMIGAN 0.01% and 0.03% should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution.
Patients should be advised that LUMIGAN® 0.01% and 0.03% contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of LUMIGAN® and may be reinserted 15 minutes following its administration.
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Symptoms of overdosage may include:

Management of overdosage:

If overdose with LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) occurs, treatment should be symptomatic.

There are no adequate and well-controlled studies of LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) administration in pregnant women.
LUMIGAN® should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

Active ingredient:

Inactive ingredients:

Manufactured by: Allergan, Inc. Irvine, CA

Lumigan Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.